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THE CLINICALLY RELEVANT ROLE TREGS PLAY IN ESTABLISHING AN 
IMMUNOSUPPRESSIVE TUMOR MICROENVIRONMENT IN MELANOMA 
 
COREY HABIB 
 
ABSTRACT 
 
The study of regulatory T cells (Tregs) is a relatively new field. Within the past few 
decades, research on Tregs has greatly deepened scientists’ understanding of the link 
between the immune system and cancer. The study of melanoma is one such cancer that 
has benefited greatly from this area of study. Tregs are a subset of CD4+ T cells (TCs) 
that are either generated in the thymus or in the periphery. The main role of Tregs in 
normal immune physiology is to suppress immune cells. This is an essential component 
in the prevention of autoimmunity. In melanoma, however, Tregs prevent components of 
the immune system from mounting a robust response to cancerous lesions and tumors.  
 
Tregs have been observed to infiltrate melanoma tumors due to chemokines and other 
soluble signaling molecules such as CCL1 and CCL22. Once Tregs accumulate inside 
melanoma tumors, they generate an immunosuppressive microenvironment in a contact-
dependent and contact-independent manner. IL-10 secretion and use of the CTLA-4 
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pathway were observed to be the most well characterized modes of suppression but other 
mechanisms are still being discovered. 
 
Clinicians can take advantage of new therapeutics to modulate the activity of Tregs. 
Exogenous administration of antibodies that bind to CTLA-4, PD-1, CCR4 and other 
receptors and molecules can prevent Treg development and action. Preventing Tregs 
from carrying out their suppressive function may allow other elements of the immune 
system, such as CD8+ TCs, to target and destroy melanoma cells. Clinicians can also 
measure the relative abundance of Tregs or use the ratio of effector TCs (Teff) and Tregs 
to predict patient outcomes and survival. 
 
More research is needed to determine that precise mechanisms of Treg infiltration and 
accumulation within the tumor and the mode of Treg suppression. This paper finds that 
there is no standard Treg identification marker. This can lead to aberrant results and 
failures such as the inability to distinguish Tregs from melanoma cells that also express 
Treg-like markers or a failure to identify other Treg subtypes. Lack of consensus also 
extends to the prognostic value of Tregs due, in part, to small sample sizes and the 
inability to accurately identify Tregs in vivo. Future research must focus on Treg 
identification, action, and the elucidation of therapeutic mechanisms. These future studies 
will ensure that clinicians have the correct information to choose the proper melanoma 
treatment that will target the specific Treg populations found within patients’ melanoma 
tumors.  
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INTRODUCTION 
 
Brief overview of the adaptive immune system 
 
The adaptive immune system has evolved to mount a large and long-lasting humoral and 
cellular response towards pathogenic threats. The two principle cell types that are 
involved in this process are B cell (BC) lymphocytes and T cell (TC) lymphocytes, 
although there are many other players. Both types of lymphocytes arise from the common 
lymphoid progenitor in the bone marrow, but their sites of maturation differ: BCs stay in 
the bone marrow during the maturation process while TCs move to the thymus. Once in 
the thymus, TCs can differentiate into different subtypes which are often characterized by 
distinct surface receptors and co-receptors and/ or transcription factors. TCs which 
express the CD4 co-receptor on their surface become CD4+ TCs, also known as helper 
TCs. Likewise, TCs that express CD8 are classified as CD8+ TCs, commonly referred to 
as either cytotoxic TCs or cytotoxic lymphocytes (CTLs). Furthermore, TCs that express 
CD25, CD4 and the transcription factor FoxP3 are classified as CD4+ CD25+ FoxP3+ 
TCs, which, henceforth will be notated as regulatory TCs (Tregs). BCs recognize soluble 
antigens using a membrane bound antibody called the BC receptor (BCR). In contrast, 
the TC receptor (TCR) of TCs only recognizes peptide antigens that are presented by 
Major Histocompatibility Complex (MHC) molecules found on nearly all nucleated 
somatic cells. Despite these differences, BCs and TCs work together with elements of the 
innate immune system to quickly identify and respond to internally- and externally-
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derived pathogenic antigens. As effective as the mammalian immune system is at 
targeting and destroying dangerous antigens, left unchecked, the immune system has 
great potential to aberrantly recognize and damage self-tissue.  
 
Regulatory T Cells 
 
Regulatory T cells (Tregs) are a subset of CD4+ TCs that, as the name suggests, have a 
regulatory function in the immune response. Since their discovery in 1969 by Japanese 
researchers Nishizuka and Sakakura, Tregs have been the focus of much interest not only 
because of their unique function but also because of their clinical adaptability in 
autoimmune diseases and cancer.1 Even within the Treg subset there exists multiple 
different variations of Tregs. In general, however, there are two separate origins of Treg 
cells which give rise to two of the best defined Treg subtypes. Tregs originating in the 
thymus are often called thymic Tregs (tTregs). Tregs that originate in the periphery, or 
extrathymically, are called peripheral Tregs (pTregs) (Figure 1).2 Currently, Tregs are 
classified as CD4+ CD25+ TCs that express Forkhead box protein 3 (FoxP3+). In 
humans, a condition known as IPEX demonstrates the autoreactive environment that is 
caused by a lack of Tregs.3 In IPEX, patients have a mutation in the Treg marker FoxP3. 
This gene codes for the master transcription factor that directs the development of Treg 
cells.4 As a result of this mutation, Treg cells fail to develop which leads to massive 
autoimmunity, and early death.5 
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Mechanism of Treg immunosuppression 
 
Interleukin 2 (IL-2) is an essential cytokine for lymphocyte regulation and an important 
growth factor for all TCs. Tregs express high levels of CD25, a component of the IL-2 
receptor (IL-2R), but express low levels of IL-2. This allows Tregs to bind exogenous IL-
2, effectively starving the surrounding conventional TCs of this cytokine (Table 1).4 In 
Figure 1. tTreg and pTreg generation occur in different compartments but 
perform overlapping function. 
tTregs are generated in the thymus due to thymic-dependent selection mechanisms. 
They suppress activated TCs, also known as Teffector cells (Teff). pTregs are 
generated extrathymically from naive CD4+ TCs (Tnaive) in sites of inflammation. 
Like tTregs, pTregs can suppress Teff (Adapted from Yadav et al., 2013).2 
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addition, through unknown mechanism, Tregs can downregulate IL-2 mRNA levels in 
conventional TCs.6 Thus, in the presence of Tregs, TCs, especially CD4+ TCs, are 
starved of IL-2 and may die via cytokine deprivation-mediated apoptosis.7 
  
Another mechanism of suppression is through Treg cytokine secretion of IL-10, TGF-B, 
and IL-35. IL-10 is a potent suppressor of inflammation via the downregulation of 
proinflammatory cytokines and cell surface receptors such as co-stimulatory receptors on 
multiple cell types (Table 1).8 TGF-B is not only needed to maintain the 
immunosuppressive function of Tregs through sustaining FoxP3 expression but is also 
thought to have immunosuppressive abilities itself through suppression of IL-2 
production and decreasing cell proliferation.9 IL-35 is a newly discovered cytokine. 
Although it shares subunits with pro-inflammatory cytokines, it is exclusively anti-
inflammatory.10 At this point, Tregs are the only known source of IL-35.10 It has been 
observed that IL-35 can reduce effector TC function and induce TC exhaustion (Table 
1).10 Furthermore, IL-34, recently discovered in 2008, has been shown to be expressed in 
certain types of FoxP3+ Tregs. This cytokine has less pronounced immunosuppressive 
effects than the other cytokines; however, IL-34 plays a role in rheumatoid arthritis and 
other autoimmune diseases in which Tregs are involved (Table 1).10 
 
Adenosine secretion by Tregs is another important mechanism of immunosuppression 
(Table 1). Adenosine is a nucleoside that is formed by the extracellular hydrolysis of 
ATP. In Tregs, this is accomplished through membrane bound CD39 and CD73 
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ectonucletidases. When bound to A2 receptors on immune cells such as conventional 
TCs, DCs, and NK cells, expansion and function of those immune cells is reduced.11 
Although adenosine can be produced by many different cells, Treg-specific knockout of 
CD39 or CD73 is associated with decreased proliferation of TCs and an increase in pro-
inflammatory cytokine secretion from CD4+ conventional TCs.12,13 
 
Tregs can also use their surface receptors to exert immunosuppressive effects in a 
contact-dependent manner. One of these receptors is CTLA-4 which is constitutively 
expressed on CD4+ FoxP3+ Tregs. Although CTLA-4 is also expressed on conventional 
TCs, its effect in Tregs is to promote immunosuppression. A study from 2000 showed 
that a Treg specific knockout of CTLA-4 in mice causes severe autoimmunity.14 One 
immunosuppressive mechanism mediated by CTLA-4 expressed on Tregs is to suppress 
the actions of antigen presenting cells (APCs) by downregulating the expression of B7 
receptors in these cells.15 Therefore, CTLA-4’s effect on APCs hinders their ability to 
effectively present antigens to conventional TCs and thus limits an adaptive immune 
response (Table 1).4 It is still unknown, however, whether Treg expression of CTLA-4 is 
essential for their suppressive effects.16  
 
Another surface receptor that Tregs use is PD-1. There are two main ligands for PD-1: 
PD-L1, which is mainly expressed on APCs, and PD-L2 which has a much varied 
expression pattern. Interestingly, Tregs express both the receptor PD-1 and its ligand PD-
L1.4 Unlike CTLA-4, PD-1 signaling plays a less critical role in immunosuppression and 
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tolerance. While CTLA-4 knockout mice die at an early age, mice without functional PD-
1 receptors do not die, although they have severe autoimmunity with symptoms similar to 
lupus (Table 1).17,18 
 
Other mechanisms of Treg function include direct cytotoxicity, inhibiting CTLs and 
ICOS expression (Table 1).19 In particular, ICOS has proven to be the subject of much 
research. ICOS is a surface co-stimulatory molecule that is essential for Tregs function. 
Anti-ICOS Ab antagonists have shown to block Treg suppressive function. ICOS is also 
important for Treg survival as it confers increased sensitivity to IL-2.20  
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Table 1. Multiple methods of Treg suppression that establishes an immune 
suppressive environment. 
 
 
 
 
 
 
Growth factor starvation High expression of CD25 coupled with minimum secretion 
of IL-2 allows Tregs to starve conventional TCs of IL-2  
Cytokine secretion IL-10 – anti-inflammatory 
TGF-B – immunosuppressive and generates pTregs  
IL-35 – anti-inflammatory and promotes TC exhaustion 
IL-34 – unknown function 
Adenosine generation Tregs catalytically hydrolyze adenosine from ATP. 
Adenosine reduces function of TCs, DCs, and NK cells 
Surface receptors CTLA-4 – immunosuppressive via the binding of B7 
family of receptors 
PD-1 and PD-L – immunosuppression via binding to 
conventional TCs and via generating pTregs 
ICOS – increased survival of Tregs 
Direct cytotoxicity  Destruction of conventional TCs via perforin and 
granzyme secretion. 
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Cancer immunology 
 
It has been known for quite some time that cancer and the immune system are linked. In 
early experiments, it was discovered that immunodeficient mice had higher rates of 
cancer occurrence.21 This is also true in human patients with primary immunodeficiencies 
such as hyper-IgE syndrome who are susceptible to certain malignancies.22 This opened 
up the door to the possibility that the presence and growth of cancer may be regulated by 
the host immune system. The very nature of cancer, however, poses a roadblock to 
researchers’ understanding of this possibility. Typically, the immune system is thought to 
protect against foreign compounds and pathogens. Cancer; however, is neither explicitly 
foreign nor an exogenous pathogen. Therefore, how does the immune system recognize 
cancer and effectively mount a specific response to it? 
 
Cancers can produce two main types of antigens which the immune system can respond 
to: tumor-specific antigens and tumor-associated antigens. Tumor-specific antigens are 
antigens that are only produced by tumor cells and not by host cells. They are often 
produced by an accumulation of point and missense mutations. Because these mutations 
produce different proteins from the host proteins, they can be targeted by immune cells, 
such as CD8+ TCs.23 On the other hand, tumor-associated antigens are antigens that are 
produced by both the tumor and host cells. They can be immunogenic in cases where, for 
instance, they are upregulated above normal physiological levels or are differentially 
expressed. Finally, self-antigens can be targeted by autoreactive TCs; however, not much 
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is known of the importance of this mechanism in the tumor clearance process. It is 
thought that strongly autoreactive TCs undergo clonal deletion during positive and 
negative selection. The TCs that remain, however, still weakly recognize self-antigens. If 
conditions are right, these autoreactive TCs can mount a limited response toward these 
self-antigens.23  
 
Both tumor-specific and tumor-associated antigens, as well as self-antigens, are displayed 
on MHC class I molecules on the surface of cancer cells which can flag them to be 
targeted by CTLs. This represents the most important immune-mediated mechanism of 
tumor clearance. The effects of CD4+ TCs on tumor clearance are less well understood. It 
is generally recognized that Th1 cells are the most important helper TCs involved in this 
process. Th1 cells are able to activate macrophages and DCs using IFN-g which can help 
with tumor clearance and aid in further presentation of tumor antigen on MHC class II 
molecules. Th2 cells are also seen to be important as well.24 
 
As a result of tumor-specific and tumor-associated antigens, an immune response can be 
mounted directed toward the tumor. Unfortunately, however, cancer cells have developed 
mechanisms that prevent an effective immune response. Tumor cells can downregulate 
MHC I molecules or upregulate certain inhibitory receptors such as PD-1 which will 
inhibit TC targeting. Tumors cells can also express immunosuppressive cytokines such as 
IL-10 and TGF-B, and also recruit Treg cells into the tumor environment.25 Melanoma 
tumors use these types of suppressive mechanisms which makes this cancer a good model 
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to study the connection between cancer and the immune system. Another potential 
difficulty in the immunological clearance of tumors is an excessive immune response 
which can cause autoimmunity. In melanoma, vitiligo, an autoimmune skin disorder, is 
associated with an immune response toward the tumor, showing the importance of not 
only mounting a response toward tumor antigens, but also mounting an appropriate and 
limited response.26 Tregs are thought to be involved in limiting the immune response.26 
 
Role of Tregs in cancer 
 
In addition to their role in immunological tolerance and prevention of autoimmunity, 
Tregs also have an important role in regulating tumor immunity. Tregs have been 
observed to infiltrate and accumulate in solid tumors of all different types of cancers.27 
Evidence for how Tregs invade tumors is relatively scarce but researchers have generally 
seen that the chemokine CCL22 is secreted by both tumor cells and by intratumoral 
macrophages. Tregs follow the gradients established by CCL22 and other chemokines 
which will lead them into the tumor.27 Tregs are also attracted to the inflammatory 
environment present in many tumors. In addition to thymic Treg infiltration, conventional 
CD4+ TCs can be induced to differentiate into pTregs due to a cytokine milieu high in 
TGF-B.27 Once in the tumor, Tregs will use their TCRs to bind to self-antigens or tumor-
associated antigens as Tregs were selected during TC differentiation due to their ability to 
bind to self-peptides with moderate-high intensity. As a result, Tregs become activated in 
the tumor environment in response to self-antigens that are released by tumor cells and 
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presented in the context of MHC receptors (Figure 2).27 Once activated, Tregs will 
generate a cytokine milieu which will suppress effector cells that are attempting to target 
and destroy the tumor. As a result, the tumor is less targeted by the immune system and is 
allowed to survive. In mice, Treg depletion results in higher rates of tumor rejection.28 
The lack of Tregs in these models are associated with altered intratumoral cytokine 
environments and increased CD8+ TC destruction of the tumors, demonstrating the 
essential role of Tregs in the regulation of cancer clearance by the immune system.28 
 
 
 
 
Figure 2. Tregs mediated the establishment of a suppressive tumor 
microenvironment. 
Tregs infiltrate the tumor environment by expressing CCR4 and binding to CCL22 
which is secreted by tumor cells. Tregs then bind to self-antigen peptides that are 
released by tumor cells and then subsequently expressed on MHC class II receptors 
on the surface of APCs, thereby activating Tregs. These activated Tregs then either 
stay in the tumor or go to nearby lymph nodes and suppress effector TCs (Adapted 
from Nishikawa and Sakaguchi, 2014).27 
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Melanoma 
 
Epidemiology and risk factors 
 
Melanoma is an important cancer model because of this cancer can be consistently 
recreated in different animals. For immunologists, melanoma is also important because 
tumors can undergo spontaneous regression, showing that the cancer is able to be targeted 
by the immune system and cleared. For these reasons, this paper will focus on melanoma 
and the role Tregs have in its immunogenicity and clearance. 
 
Melanomas are neoplasms of melanin producing melanocytes, the cells that give skin its 
dark color. Melanoma is a common and fatal cancer in certain populations. In the US, 
melanoma is the sixth most common fatal cancer among Caucasian populations.29 In 
populations that have higher levels of UV exposure, such as populations in Australia, 
melanoma is even more common as it is the fourth most common cancer among males 
and the third most common among females.30 Making matters worse, melanoma rates are 
quickly increasing, especially for the Caucasian population. Diagnoses of melanoma 
doubles roughly every 10 to 20 years.30 Besides its high rate of occurrence and mortality, 
this cancer also proves to be a financial hardship for patients and the healthcare system 
with an annual cost of almost $1 billion in just the USA.31 When melanoma metastasize, 
the cancer becomes dramatically harder to treat and the response rate to treatment drops 
to as low as 5%.32  
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The biggest risk factor for developing melanoma is exposure to ultraviolet (UV) 
radiation. Surprisingly, even a single serious sunburn event due to UV exposure in 
childhood can double the risk of developing melanoma as an adult.32 The other major risk 
factor is the presence of melanocytic nevi, more commonly referred to as moles. 
Diagnosis of melanoma can be made through visual inspection of skin by looking for skin 
lesions that are asymmetric, irregular, and large. Additionally, clinicians can use the 
presence of microphthalmia transcription factor, a melanocyte marker, in blood tests to 
aid in diagnosis.33  
 
 Pathogenesis 
 
Melanoma is a cancer that is associated with some of the highest rates of mutations. 
These mutations will effect multiple levels of cellular function including cell cycle and 
apoptotic regulation, proliferation, metabolism, and signal cascades.34 Melanoma arises 
due to genetic mutations caused by UV induced damage or other mutagenic factors. The 
most common genetic mutations in melanoma are mutations in the genes for BRAF, NF1, 
and NRAS. Melanoma normally consists of neoplastic tissue that has multiple different 
genetic mutations and not just a single one. For instance, 80% of benign nevi have the 
BRAF mutation but do not normally progress to melanoma lesions unless subsequent 
mutations are accumulated such as mutations in TERT or CDKN2A (Figure 3).34 As 
mutations accumulate in a stepwise function, pre-melanoma melanocytes grow in a radial 
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growth phase. After this, cancerous melanocytes enter a vertical growth phase in which 
they start to invade areas of the dermis and hypodermis.35 From here, melanocytes can 
enter lymphatics and capillaries and spread to secondary locations. 
 
 
 
 
 
 
 
Figure 3. Melanoma generation is due to multiple genomic mutations caused by 
UV irradiation.  
When normal melanocytes are irradiated with UVA light a single mutation can occur 
in BRAF, thereby creating a pre-melanomic nevi. At this stage, the immune system 
can prevent its excessive growth. Once more mutations accumulate, however, 
melanoma can develop and uncontrolled growth can occur (Adapted from Leonardi et 
al., 2018).34 
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SPECIFIC AIMS 
 
Melanoma is a deadly skin cancer which takes the lives of thousands of people each year. 
Traditional therapies such as excision and radiation are not effective for all patients. A 
different approach is to take advantage of a patient’s own immune system to combat this 
cancer; however, the effectiveness of such a plan may be blunted by Tregs. Therefore, 
this paper aims to determine what role Tregs play in melanoma immunology and whether 
these cells may have a therapeutic role. To accomplish this aim, this paper will: 
 
• Review the recent literature about the evidence of Regulatory T cells in the 
development, progression, and prognosis of melanoma. Focus will be put on the 
infiltration of regulatory T cells into melanoma tumors and the ability of 
regulatory T cells to generate an immunosuppressive tumor microenvironment. 
 
• Investigate the role that the new generation of immunomodulating drugs have on 
the ability of regulatory T cells to establish a suppressive microenvironment 
within melanoma tumors. 
 
• Discuss the effectiveness of regulatory T cells to establish an immunosuppressive 
tumor microenvironment and identify areas for future studies to better define 
regulatory T cells and their clinical relevance in cancer treatment. 
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LITERATURE REVIEW 
 
Treg infiltration of melanoma tumors 
 
It is well supported that Treg cells can infiltrate tumors and the surrounding areas.36-38 In 
melanoma specifically, there are two times more CD4+ CD25+ Tregs in the lymph nodes 
of patients with metastatic melanoma when compared to melanoma-free lymph nodes.39 
Furthermore, Tregs that are in cancer sites have been shown to be in direct contact with 
DCs and conventional TCs which signifies their potential involvement in tumor 
immunology. These observations underscore the importance of elucidating the 
mechanism for Treg infiltration in melanoma tumors. 
 
Skin tissue affected by melanoma expresses increased levels of the chemokines CCL22 
and CCL1.40 These chemokines interact with the CCR4 and CCR8 receptors on the 
surface of Tregs. Ligand binding leads to Treg migration to the tumor site.40-43 In 
addition, CCL22 also leads to infiltration of CD8+ CTLs into the tumor and CTL-
secreted cytokines may further enhance Treg recruitment into the tumor.44 
 
Further studies on chemokines show that CCL21 signaling via CCR7 is involved in Treg 
recruitment to melanoma tumors. A study in 2010 showed that overexpression of CCL21 
in melanoma tumors causes an increase in Treg infiltration when compared to malanomas 
that have normal or low levels of CCL21.43 More research is needed to further elucidate 
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whether chemokines are absolutely needed for Treg migration or whether they keep 
Tregs inside the tumor 
 
Function of Tregs in melanoma 
 
A strong immune response toward cancer requires the presence and action of Th1 and 
CTLs.25 Tregs have multiple methods of suppressing these cells and other immune 
responses. Not all methods, however, are used or favored in all scenarios. Examining the 
property of Tregs within melanoma environments can shed light on the mechanism of 
Treg action. In a study of Tregs taken from patients with metastatic melanoma, Tregs 
showed high expression of membrane bound CTLA-4 and production of IL-10.39 
Interestingly, however, most Treg populations did not have a high expression of TGF-B. 
When these Tregs were isolated alongside CD4+ and CD8+ conventional TCs, a dose-
dependent inhibition in proliferation of these TCs was observed. In addition, IFN-g and 
IL-2 secretion from conventional TCs was significantly reduced.39 In this same study, 
Treg suppression of CD4+ conventional TCs was observed in both a cytokine- and cell 
contact-dependent manner.39 These results support previous evidence that Tregs generate 
an immunosuppressive environment via IL-10 and CTLA-4.45 
 
Adenosine secretion is also an important component of Treg function in melanoma. Tregs 
that express CD39 and CD73 – the surface bound ectonucletidases – generate high levels 
of extracellular adenosine inside melanoma tumors, which promotes immunosuppression 
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of CD4+ and CD8+ TCs. However, Tregs are not the only cells within melanoma tumors 
to secrete adenosine. Both melanoma cells and CD4+ conventional TCs can secrete 
adenosine in a CD39-dependent and CD73-dependent manner.46 In addition, Tregs 
upregulate CD39 and CD73 levels in response to exogenous adenosine, suggesting a 
positive feedback loop in which adenosine released from melanocytes causes Tregs to 
secrete more adenosine which in turn creates an immunosuppressive environment.47 
However, the exact role of Tregs in establishing or maintaining the adenosine milieu in 
melanoma requires further research. 
 
Treg T cell receptor repertoire for melanoma 
 
Little is known about exactly what antigens are recognized by TCRs on Tregs. Part of the 
problem is that Tregs can be either thymically derived (tTregs) or peripherally induced 
from conventional TCs (pTregs), which leads to differences in the repertoire of TCRs 
expressed by each subtype. However, because these two Treg subtypes are 
phenotypically similar to each other, it is difficult to isolate subtype-specific Tregs. In the 
context of cancer and melanoma, tTregs contain TCRs that mostly recognize self-
antigens while pTregs contain TCRs that recognize non-self-, tumor-associated, and 
tumor- specific antigens (Figure 4).48,49 
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Many of the antigens associated with melanoma are endogenous self-made proteins, such 
as tyrosinases. During TC differentiation, TCs are given survival signals if their TCRs 
bind very weakly to self-antigens. This weak binding results in conventional TCs that are 
not able to mount a strong response against self-antigens and melanoma-associated 
antigens. On the other hand, TCs that bind self-antigens with higher affinity will either 
die by apoptosis or develop into Tregs. One of the most important regulators of this 
selection mechanism is a protein called autoimmune regulator (AIRE). This protein 
Figure 4. Thymically derived Tregs and peripherally induced Tregs represent 
separate TCR repertoire populations but perform overlapping function. 
nTregs, or tTregs, are directly thymically derived and express TCRs that preferentially 
recognize self-antigens. Once they bind to self-antigens inside the tumor environment, 
Tregs will promote a pro-tumor microenvironment. Peripherally derived pTregs, or 
iTregs, express TCRs that preferentially bind to tumor-associated and tumor-specific 
antigens. When iTregs bind to their cognate antigens, they will help tTregs to promote 
a pro-tumor environment (Adapted from Séralini et al., 2012).49 
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regulates the expression of self-antigens in specialized thymic epithelial cells called 
medullary thymic epithelial cells (mTECs). As a result, these antigens can be displayed to 
TCs during the negative selection step in TC differentiation.50 In AIRE-deficient mice, 
mTECs are unable to express self-antigens, such as tyrosinase related protein-1 (TRP-
1).51 This results in defective negative selection and lack of elimination of self-reactive 
TCs. In an AIRE-deficient melanoma mouse model, tumor growth is slowed principally 
due to the increase in effector TCs that are autoreactive and target self-antigens and 
melanoma-associated antigens on melanoma cells.51 In addition, an increased Teff:Treg 
ratio established by a deficiency in AIRE was correlated with reduced tumor size (Figure 
5).51 
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Figure 5. AIRE deficiency promotes tumor rejection by allowing tumor-
specific TCs to survive TC development in the thymus. 
(A) During TC development in the thymus, AIRE expression allows for peripheral 
proteins, such as TRP-1 to be expressed by mTECs. When TCs with TCRs specific 
for TRP-1 bind to receptors on mTEC that express TRP-1, these TRP-1-specific 
TCs will die via apoptosis. As a result of the lack of TRP-1-specific TCs, TRP-1-
expressing tumors are allow to survive and grow. (B) In AIRE KO models, TRP-1 
is not expressed by mTEC, thereby allowing TRP-1-specific TCs to survive. This 
will allow these TRP-1-specific TCs to attack TRP-1-expressing tumor cells, 
thereby resulting in tumor destruction and rejection (Adapted from Zhu et al., 
2013).51 
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Modulating Treg activity to increase immune response to Tumor cells 
 
The use of IL-2 in modifying Treg activity 
 
IL-2 is an important cytokine initially characterized in 1976 as a TC growth factor.52 
Administration of high dose IL-2 therapy was approved in 1998 to treat late stage and 
metastatic melanoma. IL-2 is produced mostly by CD4+ TCs but is also produced by 
CD8+ TCs and other lymphocytes. The receptor for IL-2 is IL-2R and it is expressed on 
the surface of a myriad of different cell types including TCs, BCs, and endothelial cells. 
In the most stereotypical case, IL-2R is upregulated in response to TCR stimulation and 
costimulation.53 IL-2R signaling increases effector cytotoxic functions of TCs and 
promotes differentiation and development of memory and effector cells.53 These and 
other effects of IL-2R signaling increase immune response and function.53 In mice 
deficient in IL-2, severe autoimmunity developed, suggesting that a lack of IL-2 causes 
an increase, not a decrease in immune response.54 These observations open up the 
possibility that IL-2, in addition to promoting a robust immune response, also induces 
immune regulatory function. It is believed that this IL-2-dependent regulatory function is 
mediated through Tregs.55  
  
IL-2 is essential for Treg development as IL-2 deficiency in mice results in low Treg 
numbers.56 IL-2 promotes the survival and proliferation of thymically derived tTregs.57 
Also, in conjunction with TGF-B, IL-2 supports the differentiation of conventional TCs 
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to pTregs.58 Thus, high dose IL-2 administration used in melanoma and other cancer 
therapy may not only aid in increasing the antitumor effects of conventional TCs by 
increasing their activity and survival, but may also help establish an pro-tumor 
immunosuppressive environment by enhancing Treg survival and function. In melanoma, 
high dose IL-2 therapy not only increases the overall Treg population, but also 
significantly increases a highly suppressive ICOS+ Treg subset.59 The increase in ICOS+ 
Tregs may be particularly detrimental in melanoma patients because melanoma cells 
express the ligand for ICOS. In fact, patients that had increased ICOS+ Tregs due to IL-2 
therapy had worse clinical outcomes than patients that had a less expanded ICOS+ Treg 
population.59  
 
CTLA-4 modification to inhibit Treg function  
 
CTLA-4 is an important immune checkpoint inhibitor (ICI) that is expressed mainly on 
TCs. Its primary function is to inhibit TC function by outcompeting CD28 for B7 
molecules that are expressed on APCs such as DCs (Figure 6).60 Tregs constitutively 
express CTLA-4, therefore it is accepted that Tregs have some role in the mechanism of 
action of ICIs, but whether ICIs have a direct or indirect effect on Tregs is under debate.  
 
Modulating Treg function using the CTLA-4 pathway is accomplished through the 
administration of antibodies that target CTLA-4. The proposed mechanism for how these 
antibodies effect Tregs is that they promote antibody-dependent cellular cytotoxicity 
 24 
(ADCC) directed towards Tregs.61 Two anti-CTLA-4 mAbs, Ipilimumab and 
tremelimumab, have been shown to target Tregs using FcgR-mediated ADCC in 
melanoma mouse models as well as in ex vivo experiments in melanoma patients.61 This 
Treg depletion was associated with an increased Teff:Treg ratio and reduced Treg 
infiltration into tumors.62 ADCC is thought to be accomplished via NK cells and 
macrophages that express at least some form of Fcg receptor (FcgR) which recognizes 
the IgG antibody molecules.63 
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Use of PD-1 antibody antagonists to reduce Treg function and induction 
 
The normal immunological role of PD-1 is to prevent autoimmunity or excessive immune 
response.4 PD-1 does this by inhibiting TC function and by increasing the survival and 
function of Tregs via its binding to PD-L1 and PD-L2.4 Through this binding, PD-1 
Figure 6. CTLA-4 promotes inhibitory signals in TCs thereby suppressing TC 
activity and effector function.  
Both CD28 and CTLA-4, expressed on TCs, bind to B7 on APCs, such as DCs. CD28 
promotes activation signals to TCs, allowing the TC to be activated. CTLA-4, on the 
other hand, has a higher affinity for B7 and, thus will outcompete CD28 for B7 
binding. CTLA-4 sends inhibitory signals to TCs which inhibits TC activation 
(Adapted from Postow et al., 2015).60 
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activation on effector TCs leads to TCR signal inhibition and is associated with TC 
exhaustion which is a state of reduced TC effector function.64,65  
 
PD-1 is involved in the immune-suppressive role of Tregs in melanoma. In a 2009 study, 
anti-PD-1 mAb was observed to effect Treg-mediated immunosuppression.66 When CTL 
cells which recognize melanoma antigens were cultured in vitro with Tregs, CTL 
proliferation was, as expected, hindered.66 Treatment with anti-PD-1 Ab, however, 
resulted in both an increase in frequency and total number of CTLs, suggesting that PD-1 
somehow mediates Treg suppression of CTLs.66 Clues to the mechanism of how Tregs 
use the PD-1 pathway to restrain CTL generation come with further observations that 
Tregs cause an upregulation of PD-1 and PD-L1 in CTLs when the two cell lines are 
cultured together. Addition of Anti-PD-1 mAb to the co-culture was able to prevent this 
upregulation.66 These observations suggests that in melanoma, Tregs may use the PD-1 
pathway to carry out suppressive function by both upregulating and binding to PD-1 
receptors on the surface of effector TCs. Further studies show that nivolumab, an FDA 
approved anti-PD-1 mAb, can rescue Treg-mediated suppression of CD4+ TCs as well as 
reverse Treg-mediated reduction of CD4+ TC IFN-g production.67 
 
Another effect that the PD-1 pathway has on Treg function is that PD-1 plays a large role 
in peripheral Treg induction from CD4+ conventional TCs. As stated previously, pTregs 
can be generated from CD4+ conventional TCs in response to certain signaling molecules 
such as TGF-B. In addition to a TGF-B rich milieu, PD-1 signaling has been observed to 
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promote pTreg induction when its ligand, PD-L1, is expressed on DCs.68 Blocking PD-
L1 specifically on DCs and by using systemic anti-PD-L1 Ab caused a decrease in pTreg 
development in mice.69 In addition, using PD-L1-Ig agonist to stimulate PD- increased 
FoxP3 expression in pTregs.70 These observations show that the current array of anti-PD-
1 mAb therapy used for melanoma can reduce Treg infiltration into tumors by preventing 
peripheral Treg conversion via a downregulation of FoxP3. 
 
Modulating LAG-3 receptors inhibits LAG3+ Treg populations 
 
While the CTLA-4 and PD-1 pathways are promising therapeutic targets, researchers 
have continued to look for the next generation of immunotherapeutic agents. Leukocyte 
activation gene-3 (LAG-3) is a recently discovered receptor which has profound 
immunomodulating effects.71 Like the other checkpoint receptors CTLA-4 and PD-1, 
LAG-3 can suppress TC immune response toward cancer cells through multiple 
mechanisms. One of these mechanisms includes the use of Tregs.72  
 
High expression of LAG-3 is seen in some Tregs of melanoma patients both in the 
periphery and around tumor sites. These LAG3+ Tregs have high levels of IL-10 and 
TGF-B suppressive cytokine secretion and decrease the proliferation of CD4+ TCs.72 
Thus, in melanoma, LAG-3 is associated with a Treg population which performs 
immunosuppressive functions.72 Blocking LAG-3 on Tregs decreases their suppression 
activity as seen in both in vitro and in vivo experiments.73 Unfortunately, the mechanism 
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underlying the role of LAG3 in Treg function remains unknown. However, preliminary 
clinical trial data shows promising results for LAG525 (Novartis), an IgG4 anti-LAG-3 
mAb, either alone or in combination with a PD-1 blocker.71 Therefore, the LAG-3 
pathway is a potentially exciting melanoma immunotherapeutic target which involves 
Tregs. 
 
Effects of Anti-CCR4 monoclonal antibodies on Treg function 
 
Although CCR4 is expressed on many cell types, its expression is upregulated on Tregs.41 
Because CCR4 signaling is potentially involved in Treg chemotaxis, and because the 
ligands for CCR4 are upregulated in melanoma, this and other related receptors may be a 
valuable therapeutic target.  
 
Anti-CCR4 mAb has been approved for use to treat many different types of cancers. In 
Japan, mogamulizumab was approved in 2012 to treat leukemia and lymphoma. 
Mogamulizumab was shown to reduce peripheral and intratumoral levels of Tregs and 
increased CTL response.73 Another anti-CCR4 mAb, KM2760, has been observed to 
reduce Tregs inside tumors and also promoted an ADCC response in a Hodgkin’s 
lymphoma mouse model. Similar to melanoma, Hodgkin’s lymphoma tumors secrete 
CCR4 ligands which influence Treg intratumoral invasion.74 Specifically within 
melanoma, anti-CCR4 mAb can effectively deplete Tregs in melanoma tumors. In 
addition, melanoma-specific CD4+ and CD8+ TCs were induced.75 Whether the latter 
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observation is due to a reduction in Treg presence cannot be determined. The proposed 
mechanism for CCR4 Ab antagonists is that the antibodies will block CCR4 on the 
surface of Tregs. This blockage will prevent CCR4 from binding to its multiple ligands 
and therefore will prevent the chemotaxis of Tregs into the melanoma tumor 
environment.  
 
Modulation of Tregs via the GITR pathway 
 
Glucocorticoid‐induced tumor necrosis factor‐related receptor (GITR) is constitutively 
expressed at high levels on Tregs and is upregulated in conventional TCs upon activation. 
It is therefore a good Treg marker. GITR ligand (GITR-L) has a very diverse expression 
profile but is mainly expressed on APCs and endothelial cells.76  
 
In mice, GITR stimulation results in moderately increased CD4+ and CD8+ TC 
activation, proliferation and cytokine secretion.77 More significantly, however, is its 
effect on Tregs. Administration of Fc-GITR-L, an agonist recombinant protein that fuses 
the Fc region of an Ab and the GITR-L, results in increased Treg numbers.78 
Additionally, in GITR KO mice, very low levels of Tregs are observed.76 These results 
suggests that GITR is important for Treg development and expansion. A possible 
mechanism for this is that GITR increases IL-2 sensitivity. As previously stated, Tregs 
need an exogenous source of IL-2 and in the absence of this cytokine, Tregs fail to 
survive. If GITR can increase Treg sensitivity to IL-2, then Tregs are more likely to 
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receive the signals necessary to survive. Supporting this are studies in IL-2 deficient 
mice, such as a 2015 experiment which showed that Treg death can be reversed by the 
administration of an anti-GITR mAb agonist.76 Importantly, although GITR stimulation 
causes increased Treg expansion, it also limits the suppressive abilities of Tregs. It does 
this by downregulating FoxP3 expression and activating non-immunosuppressive 
pathways such as activating the proinflammatory transcription factor, NF-kB.78 This 
makes GITR an interesting pharmacological target. 
 
Anti-GITR Ab agonists have shown promising results at clearing solid tumors. In a 
mouse melanoma model, anti-GITR Ab was observed to deplete FoxP3 levels in the 
tumor environment.27 However, this decrease may not reflect a loss of FoxP3-positive 
Tregs. Instead, the reduction in FoxP3 expression could represent Tregs that have been 
effectively shut off. Additionally, anti-GITR Ab can cause intratumoral Treg depletion 
via Fc-mediated ADCC.76 Both of these drug actions are extremely desirable because 
they result in Treg depletion mainly within the tumor, thus allowing for peripheral Treg 
populations to be preserved so that systemic autoimmunity is less likely to occur. Anti-
GITR Abs have shown promising results in mice and are currently tested in clinical 
trials.79 
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DISCUSSION 
 
Treg infiltration into melanoma tumors 
 
It is widely accepted that Tregs rely on CCR4 and CCR8 expression to chemotactically 
migrate to sites of inflammation and to resident APCs.41 On the other hand, Treg 
infiltration into tissue affected by melanoma needs more investigation. Little is known 
about what the exact signals and chemokines are that Tregs use to locate melanoma cells 
and move toward the tissue environment. Complicating matters more, Treg infiltration 
into melanoma tumors may be dependent on the stage of tumor growth. Possibly at 
earlier stages of melanoma development, the chemokine CCL2, not CCL22 or CCL1, 
acting though CCR4 may be the responsible for Treg chemotaxis.80 Not all researchers 
agree on this, however.   
 
There is great controversy as to whether chemokines, such as CCL22 and CCL1, working 
through CCR4 and CCR8 actually promote migration or just prevent Tregs from leaving 
the tumor environment. In fact, much recent research has been focused on finding CCL-
independent and CCR-independent mechanisms for Treg infiltration. This lead to 
research on vascular endothelial growth factor (VEGF) and its gradient established by 
melanoma tumors as a critical factor in causing the migration of Tregs. Neuropilin 1 
(NRP1), a co-receptor for VEGF, has been shown to be expressed on the surface of Treg 
cells. nrp1+ Tregs are seen in high concentrations inside VEGF secreting tumors.81 
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NRP1's involvement in Treg migration is not limited to melanoma, as research suggests 
that 90% of all Tregs found within cancers are nrp1+.81  
 
TGF-B-independent Treg function 
 
There is a consensus that IL-10 and TGF-B are important for Treg immunosuppression in 
a normal physiological environment. In the melanoma tumor microenvironment, 
however, the role TGF-B plays, is much less agreed upon. In a previously mentioned 
study where CTLA-4+ Tregs were isolated from melanoma patients, and cocultured 
alongside CD4+ TCs, the administration of anti-TGF-B antibodies reduced the 
suppression of conventional TCs.61 This suggests that Tregs use TGF-B as an 
immunosuppressive agent. As previously stated, however, Tregs were not the main 
source of TGF-B in this study. Instead, CD4+ conventional TCs were observed to secrete 
TGF-B. This suggests that IL-10, not TGF-B plays a large role in Treg mediated 
immunosuppression in melanoma. Treg-independent sources of TGF-B have been 
observed before in melanoma. CD4+ conventional Tregs have been observed to secrete 
TGF-B and, surprisingly, melanoma cells themselves have been shown to express FoxP3 
and secrete TGF-B.44 These observations open the door to a more complicated picture of 
how Tregs modulate a immunosuppressive microenvironment. This fact also goes 
contrary to much published literature that suggests that TGF-B is an important 
immunosuppressive cytokine that is secreted by Tregs.  
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Tregs as a prognosis marker 
 
Although it is widely accepted that Tregs hamper the immune response toward cancer, in 
reality, solely looking at Treg infiltration is an inconsistent prognostic marker when 
comparing different types of cancers. Treg presence in colorectal tumors, for instance, is 
associated with better survivability but not in lung cancer.82 When confining the 
comparison between cancers of the same type, the presence of FoxP3+ TCs was still not 
necessarily a clear prognostic tool that could predict patient survival.83 For instance, in 
one study, FoxP3 staining did not correlate with frequency of metastasis or survival of 
patients with melanoma.84 Another study, however, showed a significant correlation 
between intramelanonic Tregs and patient survival.85 For melanoma, this variation can be 
partly explained by the heterogeneity present in melanoma tumor microenvironments and 
by the different stages of tumor development. Some melanoma tissues, for example, have 
high expression of COX-2, an important enzyme in the generation of prostaglandins. In 
patients that have high melanoma tumor expression of COX-2, the presence of Tregs was 
associated with a better prognosis.85 Other melanoma tumors express the BRAF mutation, 
while others do not. These differences in melanoma expression profiles emphasizes the 
importance of distinguishing the specific tumor microenvironment. Therefore, although 
there is a general consensus that Treg infiltration is correlated with worse prognosis, 
differences in local tumor environments will prevent the usage of Treg infiltration as an 
essential prognostic marker for overall survival. With that being said, although the 
presence of Tregs in a tumor cannot accurately predict patient survival, it can still provide 
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clinician's with valuable information. In stage III melanoma, for instance, the presence of 
Tregs could predict cancer recurrence and is an independent marker for melanoma 
progression.86 These observations are supported by other studies which link the presence 
of Tregs with primary tumor progression.87 This type of information is valuable to 
determine what type of immune response the body is having toward the tumor. In turn, 
this will aid in the decision making of what treatment is best.  
 
Problems with Treg identification in melanoma 
 
Once in the tumor, Tregs are maintained by high levels of IL-10 and TGF-B produced by 
tumor cells.87 Levels of IL-10 and TGF-B are elevated in melanomas, therefore these 
cytokines are likely the reason why Treg populations are maintained. Furthermore, as 
stated previously, a prevalent IL-10 and TGF-B milieu promotes induction of 
conventional TCs to Tregs. This fact makes it difficult to determine if the Tregs found 
within tumor environment are composed of tTregs that migrated in, or are pTregs that are 
derived from conventional TCs that were already present inside the tumor. 
 
Even a cursory review of the available literature reveals variations between study 
techniques. For instance, there are large variations in Treg identification techniques 
employed by researchers. Some studies use CD4 and CD25 staining, while others use 
FoxP3 staining. Relying on only a single marker, such as FoxP3, could lead to aberrant 
results because, as was explained earlier, FoxP3 and other markers can be expressed on 
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non-Treg cells. This underscores the need for more reliable Treg markers such as 
neuropilin-1 which has just recently been discovered and, at least in one occasion, has 
been correlated with poor prognosis.10 Other studies attempt to identify the types of cells 
that are expressing Treg specific markers while other studies do not. Further still, there is 
no uniformity in where melanoma samples are taken. These variations, on top of small 
sample sizes, prevent a clear consensus.  
 
Tregs as therapeutic targets 
 
High dose IL-2 therapy may not block Tregs 
 
There is no consensus as to whether high dose IL-2 therapy is beneficial in melanoma 
patients that have high numbers of intratumoral Tregs. As stated previously, although IL-
2 therapy may increase the immune response toward tumors, its effectiveness is limited 
by its ability to stimulate immunosuppressive Tregs. It is not yet precisely known what 
the clinical effects of this limitation has on IL-2 therapy. Nevertheless, IL-2 therapy has 
numerus adverse side effects and has been shown to have limited effectiveness in treating 
melanoma. In a study by Rosenberg, just 10% of melanoma patients saw some form of 
tumor regression.88 Therefore, IL-2 therapy may have limited usefulness.  
  
Possibly a more efficient and efficacious therapy would be not to administer exogenous 
IL-2 but to target part of its receptor by using antibodies. As stated previously, the IL-2R 
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has a CD25 component. This can be targeted using anti-CD25 mAb. Unlike in 
conventional TCs, IL-2R is constitutively expressed on Tregs in the form of CD25. This 
makes it a good target for Treg modulation because the antibodies will bind more readily 
to CD25 on the surface of Tregs. Studies have shown that, in both mice and humans, 
administration of antibodies that target CD25 result in a depletion – in some studies, up to 
99% -- of Tregs in melanoma models. This depletion, however, failed to consistently 
reduce tumor growth in mice and did not have an impact on survival in humans.89 These 
results may be due to a cross reactivity of the antibody not only with Tregs but of anti-
tumor conventional TCs that also express CD25. The limited effectiveness of anti-CD25 
Abs could also be due to differences between peripheral environments and the 
environment within the tumor. In vivo experiments in mice show that anti-CD25 Abs can 
eliminate Tregs via a FcgRIII-mediated ADCC mechanism; however, this mainly occurs 
in the periphery. Inside the tumor, although FcgRIII is present, its ability to promote 
ADCC of Tregs is abrogated by an inhibitory IgG constant region receptor found in high 
concentrations inside melanoma tumors, FcgRIIb.90 Researchers have the ability to 
change the affinity of antibody-FcgR binding via modulating Fc regions. Because of this, 
further research is needed to determine the most effective class of anti-CD25 Ab which 
will elicit the strongest response both in the periphery and within the tumor environment. 
 
Another interesting approach is to administer a fusion protein that consists of IL-2 and 
diphtheria toxin. Cell death occurs when the fusion protein is endocytosed. This type of 
drug will preferentially effect cells that express high levels of IL-2R, such as Tregs. One 
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version of this, Denileukin diftitox, has been shown to reduce peripheral Tregs in 
melanoma patients, but it is not yet approved for market use.28 Researchers do not agree 
that this is a safe therapy as it may aberrantly destroy beneficial immune cells. 
 
The PD-1 pathway may not be involved in Treg suppression 
 
The exact role that the PD-1 pathway plays in Tregs is still under debate. Some 
researchers believe that Treg's suppressive abilities involve PD-1 while other researchers 
observe no difference in Treg suppressive actions in PD-1 KO mice. In one study, for 
instance, PD-L1 was observed to induce pTreg induction. When wildtype APCs 
expressing PD-L1 were cocultured with CD4+ TCs in the presence of TGF-B, conversion 
of CD4+ TCs to pTregs was observed.91 In this same study, PD-L1 was also able to 
maintain and support the Treg population by allowing FoxP3 expression to persist during 
and after activation of Tregs. This evidence is in direct contrast to other studies that show 
no link between Treg abundance and PD-1.91 In a 2014 study, although researchers 
concluded that PD-1 is highly constitutively expressed on Tregs, they did not observe a 
change in FoxP3 expression in PD-1 KO mice.69 Therefore, although there is a consensus 
that the PD-1 pathway is involved in immunosuppression in other cell types, it is still 
unknown whether it’s involved in Tregs. As a result, anti-PD-1 Ab therapy may aid 
melanoma patients in a Treg-independent fashion. 
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Efficacy of CCR4 targeted therapy  
 
Although there is a consensus that CCR4 is involved in the chemotaxis of conventional 
TCs and Tregs into peripheral sites, whether CCR4 is involved in Treg migration 
specifically into tumors is still debated. As previously discussed, many studies show that 
anti-CCR4 Abs can reduce Treg abundance in melanoma tumors. Other studies, on the 
other hand, have shown that blocking CCR4 in mice is not associated with reduced Treg 
suppression. In fact, in a study in 2016, researchers found that CCR4-deficient mice did 
not have reduced intratumoral Tregs. They also showed enhanced tumor growth.92 A 
possible explanation for these results is that, by blocking CCR4, Th17 populations were 
not able to expand in the regional lymph nodes. Because Th17 cells have been shown to 
have anti-melanoma properties, reduced Th17 populations established a more pro-tumor 
environment.92 This may suggest that drugs that target CCR4 may work in a Treg-
independent manner. In addition, this latter study underlines the urgency for more 
research into this therapy because while anti-CCR4 therapy may work in one patient and 
tumor type, it may have the opposite effect in other patients. 
 
 
Role of Treg heterogeneity on melanoma immunity 
 
As previously stated, Tregs can be put into two broad categories, or subtypes: tTregs and 
pTregs. In addition to these, there are many more different types of Tregs that are quickly 
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gaining attention.93 Unfortunately there is little consensus on the distinction between 
certain Treg subtypes. This reflects the novel nature of this research field. Here, this 
paper will discuss the different Treg types that are hotly debated in the field. 
  
Multiple activation states of Tregs 
 
Just like conventional TCs, Tregs can exist in different activation states – naïve, effector, 
and memory Tregs. Naïve Tregs have relatively lower levels of FoxP3 expression, while 
effector Tregs are antigen activated and, as a result, express and secrete numerous 
inhibitory molecules which have been previously stated.94 Memory Tregs have not been 
well characterized. There is no clear evidence that Tregs can persist for long periods of 
times without constant antigen stimulation although there are reports of Tregs that have 
elevated levels of CTLA-4 that persist in skin tissue long antigen exposure.95 These long-
lived CTLA4+ Tregs may be important in the melanoma immunosurveillance process.   
 
Distinction between tTregs, pTregs, and iTregs 
 
By far the largest subset of Tregs is the CD4+ CD25+ FoxP3+ TCs which this paper has 
categorized as tTregs. These cells arise from the thymus in response to the process of 
negative selection. They are capable of secreting IL-10 and carry out many of the 
immunosuppressive functions that have been previously outlined. pTregs make up 
another sizeable proportion of Tregs and use many of the same suppressive mechanisms 
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as tTregs. Another subtype of Tregs that has been characterized is the induced Treg 
(iTreg). These cells were CD4+ TCs which have been induced in vitro, principally with 
TGF-B and IL-2, to become Treg-like cells. Some researchers do not put iTregs in their 
own category.  
 
iTregs may share many of the same suppressive mechanisms as tTregs and pTregs; 
however, their main mode of action is to prevent DCs from activating effector TCs. In a 
2014 study carried out by Shevach and Thornton, iTregs were co-cultured with antigen 
primed DCs.2 These DCs acted as normal APCs whereby they engulfed and processed the 
antigen and expressed it on MHC class II molecules. Co-culturing these DCs with iTregs 
allowed the two cell types to interact; however, after the interactions, the DCs were 
isolated and then re-cultured with naïve antigen-specific TCs. It was found that the naïve 
antigen-specific TCs had reduced levels of activation which suggests that the iTregs 
somehow inhibited the DCs from performing the antigen presenting function.2 Upon 
further inspection, IL-10 secretion from iTregs caused an upregulation of the ubiquitin 
ligase MARCH1 in DCs. MARCH1 is thought to cause the destruction of peptide-MHC 
class II complexes on the surface of DCs, effectively preventing DCs from activating 
effector TCs (Figure 7). This IL-10- and MARCH-1-dependent mechanism is the main 
suppressive action of iTregs, although it may also occur in limited fashion in other Treg 
subsets.2 Although there is a consensus that Tregs can be induced, and many researchers 
put iTregs in the their own category, there is still debate on whether they have a unique 
suppression mechanism. 
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Tr1 cells 
 
Tr1 cells are unique Tregs because they do not have high levels of expression of FoxP3. 
Despite this, they are able to exert suppressive effects on TCs in a FoxP3-independent 
manner.96 Tr1 cells can be differentiated from other Treg cells by their high excretion of 
IL-10 and TGF-B but lack of FoxP3 expression. Tr1 cells are similar to pTregs because 
they descend from CD4+ conventional TCs outside of the thymus. The mechanism for 
Figure 7. iTregs inhibit APCs using an IL-10-dependent MARCH1 mechanism. 
iTregs, donated by the FoxP3 cell, secrete IL-10 which will cause the upregulation of 
the ubiquitin ligase MARCH1. This ligase causes the destruction of MHC class II 
molecules on APCs. This will prevent antigen presentation via the APCs and therefore 
hinder APC activity (Adapted from Shevach and Thornton, 2014).2 
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how CD4+ TCs differentiate into Tr1 cells has not been fully elucidated; however, 
evidence suggests that it is due to chronic stimulation of TCR on CD4+ TCs in the 
presence of IL-10.97 Once differentiation occurs, Tr1 cells express LAG-3, PD-1, CTLA-
4, GITR, and other normal markers that are associated with Tregs. The role of Tr1 cells is 
similar to that of nTregs; however, unlike nTregs which govern systemic 
immunosuppression, T1r cells are mainly associated with suppression of tissue-specific 
microenvironments. Within the melanoma tumor environment, there are extremely few 
published sources that have elucidated the role that Tr1 cells play. What evidence there is 
suggests a potentially surprising role for Tr1 cells. Recent evidence proposes that there is 
a possibility for Tr1 cells to promote and not suppress an antitumor environment in 
melanoma patients. For instance, Tr1 cells have the ability to synthesize granzyme B and 
perforin to destroy macrophages that promote tumor growth.98 Whether this can be 
replicated has yet to be determined. Although little is known about this cell type, research 
in this area has exploded in recent years. 
 
IL-17 Tregs 
 
Another subset of Tregs is the CD4+ CCR6+ FoxP3+ TCs that can secrete IL-17. This 
might represent a Th17 to Treg, or vice versa, conversion. This type of Treg plasticity is 
not understood but it could have something to do with the similarity in stimuli needed to 
induce differentiation. CD4+ conventional TCs require TGF-B for both Th17 and Treg 
differentiation.94 Evidence for IL-17 secreting Tregs in melanoma is limited but 
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proinflammatory cytokine secretion, such as IL-17, have been observed by Tregs inside 
melanoma tissue in some studies but is often refuted.99 Other studies in melanoma in vivo 
models have suggested that Tregs can be induced to secrete IL-17 in response to IL-6, 
another important cytokine for Th17 differentiation.100 There is no clear consensus on 
what role these cells play. It is important to note, however, that these IL-17 Tregs still 
maintain their suppressive abilities in vitro.99 
 
High ICOS expressing Tregs 
 
ICOS is a costimulatory molecule, similar to CD28, expressed on TCs that are activated 
in response to TCR stimulation. It has a role in increasing IL-10 secretion from activated 
TCs and therefore contributes to a suppressive environment.101 ICOS is expressed on TCs 
and there are Treg populations that have very high expression of ICOS – donated as 
ICOShigh Tregs – which have recently been the focus of research. ICOShigh Tregs have 
been shown to be present inside certain tumors. In melanoma, ICOShigh Tregs reside 
almost exclusively within the tumor. High ICOS expression is associated with nTregs 
that have a hyper-suppression characteristic.102 In addition, the ligand for ICOS, ICOS-L, 
is perfectly positioned to stimulate ICOShigh Tregs. It has been shown in numerous 
studies that ICOS-L is expressed on melanoma cells and within TCs and DCs within 
melanoma tumors.113 
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ICOShigh Tregs may play an important role when treating melanoma patients. In high 
dose IL-2 therapy, the ICOS+ Treg population increased more than any other Treg 
population and these Tregs showed a high activation phenotype. This increase in Treg 
population may have clinical ramification; after receiving high dose IL-2 therapy it was 
shown that melanoma patients’ clinical outcome was negatively correlated with ICOS+ 
Treg population expansion.104  
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CONCLUSION 
 
Research supports the finding that Tregs play an important role in melanoma immunity. 
Treg cells can accumulate in melanoma tumors. Although it is not known whether Tregs 
can migrate into melanoma tumors due to specific signals or are simply prevented from 
leaving. The chemokines CCL22 and CCL1 are greatly upregulated in melanoma cells 
and this chemokine milieu is associated an upregulation of the cognate receptor CCR4 on 
Tregs. Previous studies have shown that CCL22 binding to CCR4 is used for chemotaxis 
toward normal skin cells. This highly suggests that Tregs chemotactically migrate from 
peripheral sites and into the melanoma tumor environment. Once inside the tumor, other 
mechanism which have not been elucidated yet, might be responsible to prevent Treg 
escape. The role that Tregs play inside melanoma tumors is similar to their traditional 
immunoregulatory functions that have been well documented. In melanoma, It is likely 
that IL-10 and CTLA-4 are the main modes of Treg contact-independent and contact-
dependent immunosuppression. It is unlikely, however, that Treg secretion of TGF-B and 
adenosine play a major role in establishing an immunosuppressive microenvironment 
because these molecules have been observed to be secreted by other cells within 
melanoma tumors. Much more research is needed to determine the melanoma-specific 
modes of Treg immunosuppression, both in vitro and in vivo. Additionally, more research 
is needed to elucidate how other Treg subsets, such as Tr1 cells, contribute to the 
melanoma tumor microenvironment.  
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Tregs can be modulated by administration of exogenous drugs which can limit this cell 
type’s effectiveness in promoting immunosuppression. This paper does not recommend 
that high dose IL-2 therapy, which was once seen as a standard treatment, as an effective 
strategy to combat melanoma. Although IL-2 can enhance the body’s immune response 
toward melanoma,  it also stimulates Tregs. This dangerous and delicate balancing act 
can be circumvented with the use of newer generation immunotherapeutics such as PD-1, 
CTLA-4, LAG-3, GITR antibodies. These agents work to block the development and 
action of Tregs using multiple different mechanism of actions. Anti-CTLA-4 mAb seems 
to be the most well researched and well established immunotherapeutic that targets Tregs. 
More research is needed to find alternative therapeutic agents. More research is also 
needed into establishing the mechanism of action of current therapeutics. Many drugs 
have positive and clear clinical effects on melanoma patients but have poorly defined 
effects on Treg cell populations. This is true of, for example, PD-1 antibodies. Better 
defining the mechanism of action, as it relates to Tregs, for these therapeutics will help 
researchers in developing combination therapies that can target melanoma from multiple 
different directions. This paper recommends that CCR4-targeted therapy in conjunction 
with CTLA-4-targeted therapy may be sufficient to block Treg action. By preventing 
Treg recruitment and function, melanoma tumors will be preferentially invaded by 
antitumor immune cells. 
 
The prognostic value of Tregs is hotly debated in the field. As previously described, there 
is little consensus as to whether the presence of Tregs in the melanoma tumor 
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environment can accurately predict patient survival. This is mostly due to poor Treg 
identification. There is no consensus as to the most accurate technique to stain for Treg 
populations. General identification methods such as FoxP3 and CD25 that are employed 
by researchers is insufficient to label all the different Treg subtypes such as Tr1 cells 
which do not express FoxP3. The lack of consensus is also due to a deficiency in studies 
that take into account the different types and stages of melanoma cancers. More research 
is needed to establish identification methods that can predictably and accurately label 
Tregs within the tumor environment. Sample sizes should also be large enough to draw 
clear conclusions which is something that is lacking in many of the published clinical 
studies. A more accurate predictor for patient survival may not be the mere presence of 
Tregs but instead may be the Teff:Treg ratio within the tumor. 
 
Although Tregs have been the focus of much recent research, more work is needed to 
deepen our understanding of this cell type. Only in this way can the scientific community 
understand the deep and complex connections between Tregs and melanoma 
immunology. Despite the lack of consensus and research on many areas, Tregs have 
proven to be an important part of melanoma pathophysiology and treatment. 
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